These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. Colás C; Monzón S; Venturini M; Lezaun A J Allergy Clin Immunol; 2006 Apr; 117(4):810-6. PubMed ID: 16630938 [TBL] [Abstract][Full Text] [Related]
8. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030 [TBL] [Abstract][Full Text] [Related]
9. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Pfaar O; Urry Z; Robinson DS; Sager A; Richards D; Hawrylowicz CM; Bräutigam M; Klimek L Allergy; 2012 Feb; 67(2):272-9. PubMed ID: 22107266 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Worm M Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Mirone C; Albert F; Tosi A; Mocchetti F; Mosca S; Giorgino M; Pecora S; Parmiani S; Ortolani C Clin Exp Allergy; 2004 Sep; 34(9):1408-14. PubMed ID: 15347374 [TBL] [Abstract][Full Text] [Related]
12. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808 [TBL] [Abstract][Full Text] [Related]
13. 3-years' long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults. Dominicus R Eur Ann Allergy Clin Immunol; 2012 Jun; 44(3):135-40. PubMed ID: 22905596 [TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of sublingual vs subcutaneous allergen immunotherapy. Pokladnikova J; Krcmova I; Vlcek J Ann Allergy Asthma Immunol; 2008 May; 100(5):482-9. PubMed ID: 18517082 [TBL] [Abstract][Full Text] [Related]
16. Towards evidence-based medicine in specific grass pollen immunotherapy. Calderon M; Mösges R; Hellmich M; Demoly P Allergy; 2010 Apr; 65(4):420-34. PubMed ID: 20028374 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous SCIT with 2 separate allergen extracts demonstrates comparable safety compared to SCIT with a single allergen extract. Röder A; Darrelmann N; Klingenberg W; Krüll M; Suttorp N; Noga O J Investig Allergol Clin Immunol; 2009; 19(6):512-3. PubMed ID: 20128433 [No Abstract] [Full Text] [Related]
18. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Bachert C; Vestenbaek U; Christensen J; Griffiths UK; Poulsen PB Clin Exp Allergy; 2007 May; 37(5):772-9. PubMed ID: 17456225 [TBL] [Abstract][Full Text] [Related]
19. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Kleine-Tebbe J; Ribel M; Herold DA Allergy; 2006 Feb; 61(2):181-4. PubMed ID: 16409193 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life. Alvarez-Cuesta E; Aragoneses-Gilsanz E; Martín-Garcia C; Berges-Gimeno P; Gonzalez-Mancebo E; Cuesta-Herranz J Clin Exp Allergy; 2005 May; 35(5):572-8. PubMed ID: 15898977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]